Includes patients, Includes patients

Hidradenitis suppurativa (IL-1 study)

Location: Solmed Polyclinic (Zagreb), SB Medico (Rijeka)

Study Drug: Experimental biological therapy is a dual antagonist of interleukin-1α and interleukin-1β.

Main Inclusion Criteria: Patients over 18 years old who, with or after adalimumab therapy (biological therapy), exhibit symptoms consistent with moderate to severe hidradenitis suppurativa.

Status: In preparation

Start of Patient Enrollment: December 2024

Would you like to know more information on:

Hidradenitis suppurativa (IL-1 study)

Contact us

What our patients say

Newsletter

Receive regular notifications about our activities and news in treatments.

Free examinations